Hostility and platelet reactivity in individuals without a history of cardiovascular disease events

Psychosomatic Medicine

Volumn 71, Issue 7, 2009, Pages 741-747

  Shimbo, Daichi ^a   Chaplin, William ^b   Kuruvilla, Sujith ^a   Wasson, Lauren Taggart ^a   Abraham, Dennis ^a   Burg, Matthew M ^a,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary heart disease; Hostility; Platelets

Indexed keywords

ADENOSINE DIPHOSPHATE;

ADULT; ARTICLE; BAREFOOT HO; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COOK MEDLEY HOSTILITY SCALE; DISEASE ASSOCIATION; FEMALE; HOSTILITY; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGIC TEST; SCORING SYSTEM; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBUS;

ADENOSINE DIPHOSPHATE; AGGRESSION; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; CORONARY VESSELS; FEMALE; HOSTILITY; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET COUNT; RISK FACTORS;

EID: 70349693923     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0b013e3181ad18b6     Document Type: Article

References (50)

1. Badimon JJ, Zaman A, Helft G, Fayad Z, Fuster V. Acute coronary syndromes: pathophysiology and preventive priorities. Thromb Haemost 1999;82:997-1004.
2. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005;46:937-954
3. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847
4. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999;99:2192-2217
5. Miller TQ, Smith TW, Turner CW, Guijarro ML, Hallet AJ. A metaanalytic review of research on hostility and physical health. Psychol Bull 1996;119:322-348
6. Barefoot JC, Dahlstrom WG, Williams RB Jr. Hostility, CHD incidence, and total mortality: a 25-year follow-up study of 255 physicians. Psychosom Med 1983;45:59-63.
7. Barefoot JC, Smith TW. The assessment of hostility and anger. In: Siegman AW, Smith TW, editors. Anger, Hostility, and the Heart. Hillsdale, NJ: Lawrence Erlbaum Associates; 1994.
8. Dembroski TM, MacDougall JM, Costa PT Jr, Grandits GA. Components of hostility as predictors of sudden death and myocardial infarction in the multiple risk factor intervention trial. Psychosom Med 1989;51:514-522
9. Hecker MH, Chesney MA, Black GW, Frautschi N. Coronary-prone behaviors in the Western collaborative group study. Psychosom Med 1988;50:153-164
10. Kawachi I, Sparrow D, Kubzansky LD, Spiro A 3rd, Vokonas PS, Weiss ST. Prospective study of a self-report type A scale and risk of coronary heart disease: test of the MMPI-2 type A scale. Circulation 1998;98: 405-412
11. Olson MB, Krantz DS, Kelsey SF, Pepine CJ, Sopko G, Handberg E, Rogers WJ, Gierach GL, McClure CK, Merz CN. Hostility scores are associated with increased risk of cardiovascular events in women undergoing coronary angiography: a report from the NHLBI-sponsored WISE study. Psychosom Med 2005;67:546-552
12. Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol 2003;41:7S-14S.
13. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326:242-250
14. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326:310-318
15. Viles-Gonzalez JF, Fuster V, Badimon JJ. Links between inflammation and thrombogenicity in atherosclerosis. Curr Mol Med 2006;6:489-499
16. Suarez EC, Lewis JG, Kuhn C. The relation of aggression, hostility, and anger to lipopolysaccharide-stimulated tumor necrosis factor (TNF)- alpha by blood monocytes from normal men. Brain Behav Immun 2002; 16:675-684
17. Markovitz JH. Hostility is associated with increased platelet activation in coronary heart disease. Psychosom Med 1998;60:586-591
18. Markovitz JH, Matthews KA, Kiss J, Smitherman TC. Effects of hostility on platelet reactivity to psychological stress in coronary heart disease patients and in healthy controls. Psychosom Med 1996;58:143-149
19. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-1516
20. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007;115: 2196-2207
21. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006;27:647-654
22. Cook W, Medley D. Proposed hostility and pharasaic-virtue scales for the MMPI. J Appl Physiol 1954;38:414-418
23. Barefoot JC, Dodge KA, Peterson BL, Dahlstrom WG, Williams RB Jr. The Cook-Medley hostility scale: item content and ability to predict survival. Psychosom Med 1989;51:46-57.
24. Kubzansky LD, Kawachi I, Sparrow D. Socioeconomic status, hostility, and risk factor clustering in the normative aging study: any help from the concept of allostatic load? Ann Behav Med 1999;21:330-338
25. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-1834
26. Vlasova II. The effect of oxidatively modified low-density lipoproteins on platelet aggregability and membrane fluidity. Platelets 2000;11: 406-414
27. Williams MS, Coller BS, Vaananen HJ, Scudder LE, Sharma SK, Marmur JD. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro). Circulation 1998;98:742-748
28. Xu W, Favaloro EJ, Medbury H, Zoellner H. Human endothelial cells maintain anti-aggregatory activity for platelets during apoptosis. Thromb Haemost 2001;85:915-923
29. Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, Stellos K, May AE, Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420-2425
30. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Buttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-1750
31. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, Schneider DJ. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001;104:181-186
32. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Sobel BE, Schneider DJ. Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. Am J Cardiol 2003; 91:876-878
33. Gresele P, Page CP, Fuster V, Vermylen J, editors. Platelets in Thrombotic and Non-thrombotic Disorders. Cambridge: Cambridge University Press; 2002.
34. Barefoot JC, Larsen S, von der Lieth L, Schroll M. Hostility, incidence of acute myocardial infarction, and mortality in a sample of older Danish men and women. Am J Epidemiol 1995;142:477-484
35. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49: 657-666
36. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC. High post-treatment platelet reactivity identified lowresponders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-549
37. Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, Lehmann A, Lambert M, Bonnet JL, Alessi MC. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006;48:1339-1345
38. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965 (Pubitemid 36315537)
39. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events poststenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820-1826
40. Stejskal D, Vaclavik J, Lacnak B, Proskova J. Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med 2006;17:349-354
41. Mehta SR, Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003;41:79S- 88S.
42. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008;99:466-472
43. Michelson AD. P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol 2008;28:s33-s38.
44. Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, Young JB, Nissen SE. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001;103:2705-2710
45. Greenland P, Abrams J, Aurigemma GP, Bond MG, Clark LT, Criqui MH, Crouse JR 3rd, Friedman L, Fuster V, Herrington DM, Kuller LH, Ridker PM, Roberts WC, Stanford W, Stone N, Swan HJ, Taubert KA, Wexler L. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation 2000;101: E16-E22.
46. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, Fayad Z, Budoff MJ, Rumberger J, Naqvi TZ, Shaw LJ, Faergeman O, Cohn J, Bahr R, Koenig W, Demirovic J, Arking D, Herrera VL, Badimon J, Goldstein JA, Rudy Y, Airaksinen J, Schwartz RS, Riley WA, Mendes RA, Douglas P, Shah PK. From vulnerable plaque to vulnerable patient- Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol 2006;98:2H-15H.
47. Van Mieghem CA, McFadden EP, de Feyter PJ, Bruining N, Schaar JA, Mollet NR, Cademartiri F, Goedhart D, de Winter S, Granillo GR, Valgimigli M, Mastik F, van der Steen AF, van der Giessen WJ, Sianos G, Backx B, Morel MA, van Es GA, Zalewski A, Serruys PW. Noninvasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities: the integrated biomarker and imaging study (IBIS). J Am Coll Cardiol 2006;47:1134-1142
48. Everson-Rose SA, Lewis TT, Karavolos K, Matthews KA, Sutton-Tyrrell K, Powell LH. Cynical hostility and carotid atherosclerosis in African American and white women: the Study of Women's Health Across the Nation (SWAN) Heart Study. Am Heart J 2006;152:982. e7-e13.
49. Matthews KA, Owens JF, Kuller LH, Sutton-Tyrrell K, Jansen- McWilliams L. Are hostility and anxiety associated with carotid atherosclerosis in healthy postmenopausal women? Psychosom Med 1998;60: 633-638
50. Miller VM, Jayachandran M, Owen WG. Ageing, oestrogen, platelets and thrombotic risk. Clin Exp Pharmacol Physiol 2007;34:814-821